CD8A and head and neck squamous cell carcinoma: In head and neck squamous cell carcinoma (HNSCC), a novel immune signature (IMS) derived from a combined cohort identified hub genes and gene signatures for activated CD8+T cells correlated with the TIME that can predict response to immunotherapy, prognosis, immune infiltration and clinical features [91].